Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2023-07-04 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - PXS 4 pages 23.8KB
Share Issue/Capital Change Classification · 95% confidence The document is a notification about the cessation of certain securities (performance rights) for PHARMAXIS LTD, including details such as the number of securities ceased, the reason for cessation, and the updated issued capital. It is an announcement related to changes in the company's issued securities, specifically the lapse of conditional rights. The document is short (3561 characters) and focuses on a specific capital change event rather than a full financial report or other types of filings. This fits the definition of a Share Issue/Capital Change announcement (SHA).
2023-07-04 English
Application for quotation of securities - PXS 6 pages 27.9KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive scheme options exercised). This is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather a capital/financing update regarding securities issuance and quotation.
2023-07-04 English
Investor presentation 11 pages 1.5MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation | 24 May 2023' and contains detailed information about Pharmaxis' drug development programs, clinical trial updates, market opportunities, and upcoming news flow. It includes forward-looking statements, scientific and clinical data, trial designs, patient demographics, and commercial potential. The content is structured as a presentation aimed at investors, focusing on financial and strategic information rather than a formal regulatory filing or financial report. There is no indication that this is an annual or interim report, audit report, earnings release, or any other regulatory filing. The length (over 11,000 characters) and detailed content confirm it is a full presentation document rather than a brief announcement or certification. Therefore, the document best fits the category of an Investor Presentation (IP).
2023-05-23 English
PXS Announces Encouraging Results from Phase 1c Scar Study 4 pages 243.2KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 23 May 2023 from Pharmaxis Ltd announcing the results of a Phase 1c clinical trial of a topical drug treatment for skin scars. It details the study design, safety and efficacy results, and includes commentary from the lead researcher and company CEO. The document is a public announcement of clinical trial results and an investor briefing invitation, not a formal financial report or regulatory filing. It does not contain financial statements, audit information, management changes, or voting results. It is not a transcript of a call or a detailed investor presentation. The content is focused on clinical trial outcomes and company research progress, typical of a press release or media announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-05-22 English
Trading Halt 2 pages 383.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Pharmaxis Ltd regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending an announcement related to clinical trial results. The document does not contain any financial data, report content, or detailed analysis. It is a short notice about the trading halt and the pending announcement, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like financial reports or earnings releases.
2023-05-21 English
Quarterly Activities/Appendix 4C Cash Flow Report 5 pages 333.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly cash flow report for entities subject to Listing Rule 4.7B.' It contains detailed cash flow statements for the quarter ended 31 March 2023, including operating, investing, and financing activities, as well as reconciliation of cash and cash equivalents. The presence of detailed financial data for a quarter and the reference to a specific quarter end date indicate this is a quarterly financial report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-04-27 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.